TrialCell reports. Medicine2023

Bexmarilimab-induced macrophage activation leads to treatment benefit in solid tumors: The phase I/II first-in-human MATINS trial.

Jenna H Rannikko et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.